To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Completed
Novartis
Phase 3
2004-12-01
Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such
as headache, fever, muscle aches, and pains, may occur following the infusion. This study
will investigate the use of over-the-counter medicines to improve these symptoms.
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Completed
National Cancer Institute (NCI)
Phase 3
2001-12-01
RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving
adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective
in preventing bone loss.
PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus
calcium and vitamin D to see how well they work in preventing bone loss in women who are
receiving adjuvant chemotherapy for breast cancer.
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Completed
Alliance for Clinical Trials in Oncology
Phase 3
2001-12-01
RATIONALE: Zoledronate plus calcium and vitamin D may prevent bone loss in patients receiving
adjuvant chemotherapy for breast cancer. It is not yet known which regimen is more effective
in preventing bone loss.
PURPOSE: This randomized phase III trial is comparing two regimens of zoledronate plus
calcium and vitamin D to see how well they work in preventing bone loss in women who are
receiving adjuvant chemotherapy for breast cancer.
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Completed
Novartis
Phase 4
2001-10-01
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or
prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be
evaluated, as well as time in chair, quality of life and safety of Zometa.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
